Sanofi-Aventis news from FierceBiotech
NewsRegeneron licenses tech to Sanofi in $21.5M deal
Sanofi-Aventis has agreed to make five annual payments of at least $4.3 million to Regeneron Pharmaceuticals in exchange for the rights to use its Velocigene technology. Regeneron posted losses of Read more...
Acambis shares soar on $548M buyout deal
Shares of Acambis PLC soared after Sanofi-Aventis announced that it planned to buy the vaccine developer for $548 million. Aside from the smallpox vaccine ACAM2000, which recently won a 10-year, $425 Read more...
4. Sanofi-Aventis - Top 15 R&D Budgets
Who: Sanofi-Aventis Based: France 2006 Pipeline Budget: $6.44 billion (€4.40B) 2007 Pipeline News: Sanofi-Aventis has been Read more...
Big Pharma takes an interest in cancer vaccines
For two decades, biotech companies have struggled to develop therapeutic cancer vaccines designed to treat the disease by stimulating the immune system to attack cancer cells without harming normal Read more...
Sanofi signs stem cell pact in China
Sanofi-aventis announced that it has signed a deal to collaborate with the Chinese Academy of Medical Sciences on stem cell research. Sanofi hopes to isolate acute myeloid leukemia stem cells and Read more...
4. Sanofi-Aventis and Oxford BioMedica
Who: Sanofi-Aventis With: Oxford BioMedica What: $690 million licensing deal Summary: Sanofi-Aventis hopped on the Read more...
| Press ReleasesPRESS RELEASE: Regeneron Initiates Major Global Collaboration with Sanofi-aventis Regeneron Initiates Major Global Collaboration with Sanofi-aventis to Develop and Commercialize Fully-Human Therapeutic Antibodies Sanofi-aventis plans to increase its stake in Regeneron to Read more... Sanofi-aventis Announces New Research Center in Oro Valley ORO VALLEY, Ariz., Nov. 15 /PRNewswire-FirstCall/ -- Sanofi-aventis, a leading global pharmaceutical company, hosted a groundbreaking ceremony today for a new Research Center in Oro Valley. The Read more... PRESS RELEASE: Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit against Sanofi-Aventis Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit against Sanofi-Aventis NEW YORK -- Coughlin Stoia Geller Rudman & Robbins LLP (“Coughlin Stoia”) (Read more... PRESS RELEASE: Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine SWIFTWATER, Pa., and LYON, France, Nov. 7 -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, Read more... PRESS RELEASE: FDA Sends Sanofi Warning Letter for Ketek Study FDA Sends Sanofi Warning Letter for Ketek Study ROCKVILLE, Md., Oct. 24, 2007--The FDA posted on its web site a letter to Sanofi-aventis regarding a study with the antibiotic Ketek. DEPARTMENT OF Read more... |
Get more Sanofi-Aventis coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets